Investors

Financials & Filings

Filing date Form Description Filing Group View
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
UPLOAD

UPLOAD

Other
S-3

Simplified registration form

Registration Statements
DEFM14A

Definitive proxy statement relating to merger or acquisition

Mergers & Acquisitions
UPLOAD

UPLOAD

Other
PRER14A

Proxy soliciting materials. Revised preliminary material

Proxy Filings
CORRESP

CORRESP

Other
UPLOAD

UPLOAD

Other
PRER14A

Proxy soliciting materials. Revised preliminary material

Proxy Filings
CORRESP

CORRESP

Other

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.